

A KINETIC STUDY
ON OXYTOCINASE (CYSTINE AMINOPEPTIDASE)
THE EFFECT OF REMOVAL OF SIALIC ACID

T. BARTH*, L. YMAN, B. KULLING and J. BARTHOVÁ**

Uppsala Universit,

Farmaceutiska fakulteten, Stockholm, Sweden

Received May 29th, 1970

Neuraminidase treatment of oxytocinase, resulting in complete removal of sialic acid was performed and its influence on some kinetic properties of the enzyme was studied. Both K_m (L-leucine-*p*-nitroanilide) and K_i H-Cys(Bzl)-Pro-Leu-GlyNH₂ were found to increase in the pH interval 6–8. A relative change in properties was observed at pH values where the conformational change of oxytocinase takes place.

Oxytocinase from human retroplacental serum has been shown to be a glycoprotein^{1–3} acting as an aminopeptidase with very broad specificity^{1,2,4}. The enzyme molecule contains in addition to other carbohydrates (a total of 44%) about 40 sialic acid residues, all of which can be removed by α -neuraminidase³ without change in specificity¹. The sialic acid is involved in a conformational change of the oxytocinase molecule around pH 8.5 (ref.^{5,6}) which does not take place in the enzyme when sialic acid is removed. Thus the removal of sialic acid, at physiological pH, will not result only in a decrease in total negative charge and in a change of charge distribution on the molecular surface but also in a change of conformation.

The present communication reports on some studies concerning the influence of the above mentioned changes on the catalytic properties of oxytocinase.

EXPERIMENTAL

Oxytocinase was prepared as described by Yman³. A stock solution of pure enzyme ($E_{280} = 0.085$ corresponding to a conc. 0.110 mg/ml taking human albumine as the standard in Lowry

* Present address: Institute of Organic Chemistry and Biochemistry, Czechoslovak Academy of Sciences, Prague 6.

** Present address: Department of Biochemistry, Charles University, Prague 2.

method) in 0.001M sodium phosphate buffer, pH 7.4 was kept at +4°C for a period of several months without loss of activity.

Sialic acid free oxytocinase was prepared by the incubation of 5 ml of stock solution of oxytocinase with 0.4 ml α -neuraminidase (Serva Entwicklungslabor, Heidelberg) at pH 7.4 for 5 hours at 37°C. The incubation mixture was subjected to gel filtration on Sephadex G-200 as described for oxytocinase³ in order to remove the neuraminidase. The pooled fractions were dialysed against 0.001M sodium phosphate buffer, pH 7.4 for 24 hours and kept at 4°C. The enzyme preparation obtained was homogenous in polyacrylamide gel electrophoresis, giving only one zone both after protein staining and after incubation with leucine- β -naphthylamide as previously described⁷.

The substrate, L-leucine-*p*-nitroanilide, was synthesized by Dr E. Kasáfirek, Research Institute for Pharmacy and Biochemistry, Prague. The inhibitor, H-Cys(Bzl)-Pro-Leu-GlyNH₂ was prepared by Dr K. Jošt, Institute of Organic Chemistry and Biochemistry, Czechoslovak Academy of Sciences, Prague.

The enzymic reaction with L-leucine-*p*-nitroanilide as substrate was carried out at 37°C in thermostated cuvettes. The incubation mixture in a total volume of 1.0 ml consisted of 0.1M sodium phosphate buffer pH 6.16–7.95, 0.2–1.2 mM substrate and 5 μ l of stock solution of intact oxytocinase or 100 μ l of neuraminidase-treated oxytocinase (the amount was chosen so as to get approx. the same activity as for the intact oxytocinase). The reaction rate was determined by following the changes of optical density at 406 nm which was read off at one minute intervals for 7–8 minutes.

The inhibitory effect of the peptide was estimated in the above mentioned substrate concentration range. The final concentration of the inhibitor was 0.0125 mM and 0.050 mM.

Michaelis constant (K_m), maximal velocities (V) and inhibition constants (K_i) were determined graphically using a double reciprocal plot⁸⁻¹⁰.

RESULTS AND DISCUSSION

As shown by Tuppy and coworkers¹ the substrate specificity of oxytocinase, at least so far the chromogenic substrates used is concerned, is unaffected by treatment by α -neuraminidase. However, when the changes of the enzyme molecule caused by the removal of all the sialic acid residues are taken into account certain alternations of the enzymic properties would be expected.

Fig. 1 shows the pH dependence of the Michaelis constant and maximal velocities for the intact and sialic free enzyme with L-leucine-*p*-nitroanilide as substrate. The curves found for oxytocinase are similar to those obtained earlier by Yman and Sjöholm⁶ with L-leucine- β -naphthylamide as substrate but the pH dependence of pK_m is in this case more complex. In the whole pH range studied the pK_m of the neuraminidase-treated enzyme is lower than that of oxytocinase, while the shape of the curve is only moderately changed. For example, at pH 7.4 the K_m values for the oxytocinase and sialic acid free oxytocinase were found to be $5 \cdot 10^{-4}$ and $3 \cdot 10^{-3}$ M, respectively. As the amount of enzyme in the incubation mixture was chosen to give about the same activity in both cases no information was obtained concerning the effect of removal of sialic acid on the absolute rate of the catalytic reaction. The

identical shape of the curves shows that the same groups are involved in the catalytic reaction in both cases.

The peptide (H-Cys(Bzl)-Pro-Leu-GlyNH₂) is not hydrolyzed by oxytocinase and it is as shown by Beránková and coworkers^{11,12} a potent inhibitor of the enzyme. Compared to other structural fragments of the oxytocin molecule it is the most effective inhibitor. This tetrapeptide was found to be a competitive inhibitor of both intact and sialic free oxytocinase in the whole pH range studied (*e.g.* Fig. 2). The affinity of oxytocinase for the peptide is about 70 times higher than that for the substrate. At pH 7.4 K_i was found to be $7 \cdot 10^{-6}$ M as in the case of K_m , it was increased by neuraminidase treatment of the enzyme (Fig. 3).

The intact enzyme exist in two form in the alkaline pH range, and although only one form is present at neutral and slightly acid pH, the Michaelis-Menten kinetics are too irregular and complex in this range to be evaluated according to Dixon⁹. No conclusions can be therefore drawn from the curves about the nature of the groups important for the formation of the enzyme-substrate complex. When the pH dependence of K_m and K_i of both enzymes is compared it is obvious that at pH




FIG. 1

pH Dependence of Michaelis Constant (— $\log K_m$, full line) and Maximal Velocities ($\log m \cdot \text{min}^{-1} \cdot 10^6$, broken line) for Oxytocinase (1) and Neuraminidase Treated Enzyme (2)




FIG. 2

Double Reciprocal Plot Showing the Competitive Inhibition of Oxytocinase by H-Cys(Bzl)-Pro-Leu-GlyNH₂ at pH 6.6

Reaction without inhibitor (1), inhibitor concn. $1.25 \cdot 10^{-5}$ M (2), inhibitor concn. $5 \cdot 10^{-5}$ M (3). Abscissa: M^{-1} , ordinate: $\text{M}^{-1} \cdot \text{min} \cdot 10^{-6}$.

According to the present state of knowledge it seems probable that sialic acid has a secondary effect and it is not directly involved either in the formation of the enzyme substrate complex or in the catalytic reaction. However, its presence on the surface of the protein molecule will necessarily influence the distribution of charges in the enzyme molecule which may facilitate the formation and/or improve the stability of the enzyme substrate complex.

This work was carried out at the Department of Pharmacognosy, Faculty of Pharmacy, during a visit of one of the authors (T.B.). The fellowship supplied by the Royal Swedish Academy of Engineering Sciences is gratefully acknowledged. The authors are greatly indebted to the Head of the Department, Professor F. Sandberg, for valuable discussions and support.

REFERENCES

1. Tuppy H., Wiesbauer U., Wintersberger E.: *Monatsh.* 94, 321 (1963).
2. Sjöholm I., Yman L.: *Acta Pharm. Suec.* 3, 377 (1966).
3. Yman L.: *Acta Pharm. Suec.* 7, 29 (1970).
4. Čiháň M., Beránková Z., Rychlík I., Šorm M.: *This Journal* 26, 2632 (1961).
5. Sjöholm I., Yman L.: *Acta Pharm Suec.* 3, 389 (1966).
6. Yman L., Sjöholm I.: *Acta Pharm. Suec.* 4, 13 (1967).
7. Yman L., Kulling B.: *Acta Pharm. Suec.* 6, 313 (1969).
8. Lineweaver H., Burk D.: *J. Am. Chem. Soc.* 56, 658 (1934).
9. Dixon M.: *Biochem. J.* 55, 161 (1953).
10. Barth T., Yman L.: Unpublished results.
11. Beránková Z., Rychlík I., Šorm F.: *This Journal* 25, 2575 (1960).
12. Beránková Z., Rychlík I., Šorm F.: *This Journal* 26, 1708 (1961).